S Cresta
Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
Joerger M, Hess D, Delmonte A, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C. Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968). Br J Clin Pharmacol 2015; 80:128-38.
03.06.2015Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).
03.06.2015Br J Clin Pharmacol 2015; 80:128-38
Joerger M, Hess D, Delmonte Angelo, Gallerani E, Fasolo A, Gianni L, Cresta S, Barbieri P, Pace S, Sessa C
Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
Sessa C, Marsoni S, Zanna C, Carminati P, Gatti B, Capri G, Zaniboni A, D'Incalci M, Zucchetti M, Trigo J, Hess D, Malossi A, Rota Caremoli E, Baselga J, Cerny T, Cresta S, Gianni L. Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:561-8.
01.03.2007Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors
01.03.2007Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007; 18:561-8
Sessa C, Marsoni S, Zanna C, Carminati P, Gatti B, Capri G, Zaniboni A, D'Incalci M, Zucchetti M, Trigo J, Hess D, Malossi A, Rota Caremoli E, Baselga J, Cerny Thomas, Cresta S, Gianni L